We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+23.95%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.74B
AUM Growth
+$946M
Cap. Flow
+$105M
Cap. Flow %
1.56%
Top 10 Hldgs %
63.65%
Holding
393
New
188
Increased
79
Reduced
42
Closed
65

Top Buys

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$76M
2
NVO
Novo Nordisk
NVO
+$43.1M
3
FRPT icon
Freshpet
FRPT
+$41.5M
4
SBUX icon
Starbucks
SBUX
+$31.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$30.3M

Top Sells

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$79.6M
2
PTCT icon
PTC Therapeutics
PTCT
+$76M
3
GRFS
Grifois
GRFS
+$50.6M
4
STAA icon
STAAR Surgical
STAA
+$47.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$40.5M

Sector Composition

Rank Sector Weight
1 Healthcare 31.9%
2 Technology 5.53%
3 Consumer Discretionary 5.27%
4 Communication Services 2.01%
5 Consumer Staples 1.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PENN icon
26
PENN Entertainment
PENN
$2.67B
$40.5M 0.6%
2,103,666
+690,078
+49% +$12.9M
DYN icon
27
Dyne Therapeutics
DYN
$4.71B
$38.8M 0.58%
3,064,000
+504,000
+20% +$5.75M
AGIO icon
28
CALL
Agios Pharmaceuticals
AGIO
$1.82B
$36.1M 0.54%
+900,000
New +$33.9M
MDB icon
29
MongoDB
MDB
$28.8B
$34.9M 0.52%
112,399
+8,903
+9% +$2.29M
OFIX icon
30
Orthofix Medical
OFIX
$496M
$32.7M 0.49%
2,236,000
-742,000
-25% -$9.74M
AGIO icon
31
Agios Pharmaceuticals
AGIO
$1.82B
$30.7M 0.45%
764,000
-404,000
-35% -$15.2M
SBUX icon
32
Starbucks
SBUX
$118B
$30.1M 0.45%
+356,107
New +$31.9M
IMCR icon
33
Immunocore
IMCR
$1.65B
$29.9M 0.44%
824,000
+146,000
+22% +$4.96M
BMY icon
34
Bristol-Myers Squibb
BMY
$134B
$29.3M 0.43%
+649,733
New +$30.3M
AVNS
35
DELISTED
Avanos Medical
AVNS
$28.9M 0.43%
2,500,000
+464,000
+23% +$5.43M
SNY icon
36
Sanofi
SNY
$103B
$28.9M 0.43%
+612,000
New +$29.5M
IRON icon
37
Disc Medicine
IRON
$2.93B
$28.8M 0.43%
436,000
– –
DDOG icon
38
Datadog
DDOG
$97.4B
$28.8M 0.43%
202,061
+52,061
+35% +$7.17M
BABA icon
39
Alibaba
BABA
$305B
$27.9M 0.41%
156,000
+98,000
+169% +$12.8M
TMO icon
40
Thermo Fisher Scientific
TMO
$212B
$26.7M 0.4%
55,016
+25,052
+84% +$11.7M
AUTL
41
Autolus Therapeutics
AUTL
$484M
$25.4M 0.38%
15,600,000
+3,600,000
+30% +$7.03M
MDT icon
42
Medtronic
MDT
$111B
$25.3M 0.37%
265,257
+1,257
+0.5% +$116K
S icon
43
CALL
SentinelOne
S
$6.87B
$24.7M 0.37%
+1,400,000
New +$25.1M
NBIS
44
Nebius Group N.V.
NBIS
$54B
$23.9M 0.36%
213,280
+89,280
+72% +$6.2M
BCYC
45
Bicycle Therapeutics
BCYC
$270M
$23M 0.34%
2,978,000
+178,000
+6% +$1.34M
GRFS
46
Grifois
GRFS
$5.35B
$22.3M 0.33%
2,236,000
-5,062,000
-69% -$50.6M
CVS icon
47
CVS Health
CVS
$134B
$22M 0.33%
+291,819
New +$20M
AXGN icon
48
Axogen
AXGN
$2.46B
$21.4M 0.32%
1,200,000
+88,681
+8% +$1.29M
IRWD icon
49
Ironwood Pharmaceuticals
IRWD
$728M
$21.2M 0.31%
16,150,000
– –
HUBS icon
50
HubSpot
HUBS
$12.3B
$21.1M 0.31%
45,018
+22,914
+104% +$11.5M
1
2
3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return

Armistice Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Armistice Capital held 393 positions worth $6.74B, up 16% from $5.8B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Armistice Capital's Q3 2025 filing shows 188 new, 79 increased, 42 reduced and 65 closed positions. Its largest new stake was Novo Nordisk: 736,000 shares worth $40.8M. The largest sale was Supernus Pharmaceuticals, an estimated $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Armistice Capital's largest Q3 2025 buy was Novo Nordisk: 736,000 shares worth $40.8M.
  • Armistice Capital added most to Dentsply Sirona in Q3 2025, an estimated $76M increase.
  • Armistice Capital's biggest Q3 2025 reduction was Supernus Pharmaceuticals, cutting an estimated $79.6M.
  • Armistice Capital fully exited STAAR Surgical in Q3 2025, selling an estimated $47.2M.
  • Armistice Capital's ten largest holdings make up 64% of its $6.74B portfolio in Q3 2025.
  • Armistice Capital opened 188 new positions and closed 65 in Q3 2025.
  • Armistice Capital's portfolio value rose 16% quarter-over-quarter to $6.74B.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.